Topelia Aust Limited (ABN 36 652 771 670) (Topelia) is an unlisted biotechnology company focused on developing and commercialising its proprietary Antiviral Triple Therapy (ATT) for coronavirus infection.
Topelia proposes to offer its ATT treatment alongside the current global vaccination program to treat and vaccinate our way out of this coronavirus pandemic. As countries experience persistent coronavirus outbreaks, it is vital to fast track the production of a safe antiviral medical treatment.
The novel ATT comprises regulator-approved medications prescribed for decades, with exceptional safety profiles.
Having previously achieved success in commercialising a Triple Therapy for Helicobacter pylori, the principals of Topelia have now turned their attention to triple therapy for coronavirus.